SCHEMBL4292792

SCHEMBL4292792

O=C(c1ncn([C@H](c2ccccc2)C2(O)CCCCC2)c1-c1ccccc1)N1CCNC[C@H]1Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA4 P22748 2/20 0.43
CA9 Q16790 2/20 0.43
DPP4 P27487 5/20 0.38
REN P00797 2/20 0.38
DPP7 Q9UHL4 2/20 0.37
USP19 O94966 5/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
SCD5 Q86SK9 1/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
CYP3A4 P08684 1/20 0.34
ABHD6 Q9BV23 1/20 0.34
DAGLA Q9Y4D2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4292797 1.00 CA1 (0.43) CA1CA2CA4CA9DPP4
Hydrochloric Acid SCHEMBL4288900 0.99 CA1 (0.42) CA1CA2CA4CA9DPP4
Hydrochloric Acid SCHEMBL4288897 0.99 CA1 (0.42) CA1CA2CA4CA9DPP4
SCHEMBL13705358 0.89 CA1 (0.43) CA1CA2CA4CA9DPP4
Hydrochloric Acid SCHEMBL4282171 0.89 CA1 (0.43) CA1CA2CA4CA9DPP4
SCHEMBL4283241 0.82 CA1 (0.45) CA1CA2CA4CA9DPP4
SCHEMBL13705368 0.78 CA1 (0.42) CA1CA2CA4CA9DPP4
Hydrochloric Acid SCHEMBL4288873 0.78 CA1 (0.42) CA1CA2CA4CA9DPP4
SCHEMBL4751910 0.78 CA1 (0.42) CA1CA2CA4CA9DPP4
SCHEMBL4293038 0.78 CA1 (0.48) CA1CA2CA4CA9DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT CA1 2275/4885CA2 218/4885CA4 296/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT CA1 2275/4885CA2 218/4885CA4 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.